5 minute read
Jan. 28, 2023

Emraclidine: A Pioneering M4 Positive Allosteric Modulator


M4 positive allosteric modulator Ph. II for schizophrenia discovery not disclosed Lancet, December 17, 2022 Cerevel Therapeutics, Cambridge, MA

Drug Hunter Team

Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor (GCPR) and is the only selective M4 PAM in clinical development . The molecule was highlighted by Cerevel at JPM ‘23 as it has shown promising early results in schizophrenia with several Ph. II trials enrolling ( [...]



Other molecules you may be interested in